# BeOne Medicines (formerly BeiGene)

Source: https://onco.cc/companies/beone/  
OnCo record `beone` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BeOne Medicines makes Brukinsa, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab.

## Summary

BeOne Medicines, formerly BeiGene, based in Basel and Beijing and listed as ONC, makes Brukinsa, or zanubrutinib, the leading BTK inhibitor, and tislelizumab, and is the Asia partner for zanidatamab. Its pipeline includes sonrotoclax, a BCL-2 inhibitor, and the BTK degrader BGB-16673, with the RATIONALE-302 trial linked, and John Oyler and Jie Wang among the people connected. OnCo links it to chronic lymphocytic leukaemia, mantle cell and follicular lymphoma, gastric and nasopharyngeal cancer, and to bottlenecks on acquired resistance, regulatory divergence and unrepresentative trials, which its China-to-global model bears on. Whether a BTK degrader can overcome resistance to its own BTK inhibitor is the open question. Zanubrutinib and zanidatamab have their own pages.

## Fields

- Kind: Company
- Last checked: 2026-09-04
- Also known as: BeiGene; BeiGene USA; Inc.; BeOne; BeOne (BeiGene); GW Pharmaceuticals Ltd; GW Pharmaceuticals
- HQ: Basel / Beijing
- Type: biotech
- Website: https://www.beonemedicines.com
- Ticker: ONC

## Sources

- Official website: https://www.beonemedicines.com

## Connected records

- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [BGB-16673](https://onco.cc/drugs/bgb-16673/), [BGB-43395](https://onco.cc/drugs/bgb-43395/), [Pamiparib](https://onco.cc/drugs/pamiparib/), [Sonrotoclax](https://onco.cc/drugs/sonrotoclax/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [Zanidatamab](https://onco.cc/drugs/zanidatamab/), [Zanubrutinib](https://onco.cc/drugs/zanubrutinib/)
- trials: [A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies](https://onco.cc/trials/nct05006716/), [A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Sol](https://onco.cc/trials/nct06427941/), [A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Darat](https://onco.cc/trials/nct04973605/), [A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLC](https://onco.cc/trials/nct07815223/), [A Study Investigating the Efficacy and Safety of Alcestobart (LBL-007) Plus Tislelizumab in Combination With Bevacizumab Plus Fluoropyrimidine Versus ](https://onco.cc/trials/nct05609370/), [A Study of BGB-11417 in Participants With Myeloid Malignancies](https://onco.cc/trials/nct04771130/), [A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors](https://onco.cc/trials/nct06970743/), [A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL](https://onco.cc/trials/nct04521231/), [A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia](https://onco.cc/trials/nct07134088/), [A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors](https://onco.cc/trials/nct06846671/), [A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer](https://onco.cc/trials/nct05635708/), [A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphom](https://onco.cc/trials/nct05100862/), [A Study to Evaluate Efficacy and Safety of Tislelizumab Plus Chemotherapy for Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Adenocarcinoma and Esophageal Squamous Cell Carcinoma in Racial and Ethnic Minority Patients in the United States](https://onco.cc/trials/nct07554521/), [A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib](https://onco.cc/trials/nct04170283/), [A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma](https://onco.cc/trials/nct06973187/), [A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström Macroglobulinemia](https://onco.cc/trials/nct05952037/), [A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)](https://onco.cc/trials/nct06943872/), [A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies](https://onco.cc/trials/nct06634589/), [A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia](https://onco.cc/trials/nct07277231/), [A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic Leukemia](https://onco.cc/trials/nct06637501/), [A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants](https://onco.cc/trials/nct05661955/), [A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refrac](https://onco.cc/trials/nct06742996/), [A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantl](https://onco.cc/trials/nct04002297/), [A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.](https://onco.cc/trials/nct06697184/), [Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer With a High Tumor Burden](https://onco.cc/trials/nct07715396/), [Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer](https://onco.cc/trials/nct06520683/), [ALPINE](https://onco.cc/trials/alpine/), [ASPEN (Waldenström macroglobulinaemia)](https://onco.cc/trials/aspen-wm/), [BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease](https://onco.cc/trials/nct07492641/), [CaDAnCe-304](https://onco.cc/trials/cadance-304/), [CELESTIAL-TNCLL](https://onco.cc/trials/celestial-tncll/), [Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)](https://onco.cc/trials/nct04379635/), [HERIZON-BTC-01](https://onco.cc/trials/herizon-btc-01/), [HERIZON-GEA-01](https://onco.cc/trials/herizon-gea-01/), [Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer](https://onco.cc/trials/nct03519230/), [MRD-guided Adjuvant Tislelizumab and Chemotherapy in Resected Stage IIA-IIIB NSCLC](https://onco.cc/trials/nct05286957/), [Neoadjuvant Long-course Chemoradiation Plus PD-1 Blockade for Mid-low Locally Advanced Rectal Cancer](https://onco.cc/trials/nct05245474/), [RATIONALE-302](https://onco.cc/trials/rationale-302/), [RATIONALE-306](https://onco.cc/trials/rationale-306/), [Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma](https://onco.cc/trials/nct05479994/), [Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma](https://onco.cc/trials/nct05471843/), [Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma](https://onco.cc/trials/nct03967977/), [Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors](https://onco.cc/trials/nct03736889/), [Tislelizumab in People With Colorectal Cancer](https://onco.cc/trials/nct06529523/), [Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC](https://onco.cc/trials/nct06456138/), [Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader](https://onco.cc/trials/nct05294731/)
- cancers: [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/), [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Mantle cell lymphoma](https://onco.cc/cancers/mantle-cell-lymphoma/), [Nasopharyngeal carcinoma](https://onco.cc/cancers/nasopharyngeal/), [Oesophageal cancer](https://onco.cc/cancers/esophageal/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- people: [Jie Wang](https://onco.cc/people/wang-jie-cams/), [John Oyler](https://onco.cc/people/oyler-john/)
- bottlenecks: [Acquired resistance to every therapy](https://onco.cc/bottlenecks/b-resistance/), [Regulatory divergence between regions](https://onco.cc/bottlenecks/b-regulatory-fragmentation/), [Trials do not represent the people who get cancer](https://onco.cc/bottlenecks/b-trial-diversity/)
- key papers: [Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study](https://onco.cc/key-papers/paper-harding-lancet-oncol/)
- institutions: [National Medical Products Administration / Center for Drug Evaluation](https://onco.cc/institutions/nmpa-cde/)

---
JSON: https://onco.cc/api/v1/entities/beone.json